Health
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia – MD Linx
MDLinx original journal summary on Pneumonia, Infectious Disease from International Journal of Infectious Diseases
In the treatment of severe SARS-CoV-2 pneumonia (SSP), tocilizumab has been used with the aim to relieve the cytokine release syndrome (CRS)-induced acute respiratory distress syndrome (ARDS). Researchers here investigated the patients in whom it might benefit the most. Tocilizumab on a compassionate-use basis was provided to hospitalized patients with SSP (excluding intensive care and intubated cases) who required oxygen support to have a saturation > 93%. They studied a total of 207 patients and…
-
Business17 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
General23 hours agoMichael Beatty, veteran current affairs journalist and animal welfare advocate, dies aged 76
-
Noosa News16 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News13 hours agoTips to improve engagement – Proctor